Gene Expression Profiling of HR Pathway Predicts Olaparib Susceptibility in Malignant Pleural Mesothelioma

Study Background and Research Question

Malignant pleural mesothelioma (MPM) is an aggressive tumor with a poor prognosis, typically originating from the pleural lining. Despite the use of standard chemotherapy regimens such as pemetrexed and cisplatin, response rates remain suboptimal, with the majority of patients experiencing recurrence or disease progression (source: Borchert et al. 2019). The underlying causes of therapeutic resistance are not fully understood but may involve enhanced DNA repair mechanisms within tumor cells. In this context, the homologous recombination (HR) repair pathway—responsible for repairing double-strand breaks (DSBs) in DNA—emerges as a critical determinant of genomic stability and chemoresistance. The research question addressed by Borchert et al. centers on whether defects in the HR pathway, collectively described as the "BRCAness" phenotype, can serve as biomarkers for increased sensitivity to poly (ADP-ribose) polymerase (PARP) inhibition in MPM. The study investigates if gene expression profiling of HR components can predict which tumors may respond favorably to olaparib, a clinically approved PARP inhibitor.

Key Innovation from the Reference Study

The central innovation of this study lies in its application of transcriptomic profiling to stratify MPM tumors according to their HR repair status. By focusing on genes associated with the BRCAness phenotype—including but not limited to BRCA1, BRCA2, and BAP1—the authors offer a nuanced method to identify tumors with functional HR defects. Notably, they demonstrate that BAP1-mutated MPM cell lines exhibit heightened sensitivity to PARP inhibition, especially when olaparib is combined with cisplatin. This approach broadens the therapeutic window for PARP inhibitors, which are conventionally reserved for tumors harboring canonical BRCA1/2 mutations. The identification of BAP1 and other HR-related gene alterations as predictors of olaparib response expands potential clinical indications to a significant subset of MPM patients (source: Borchert et al. 2019).

Methods and Experimental Design Insights

Borchert et al. employed a multipronged approach involving both in vitro and transcriptomic analyses. Three MPM cell lines, stratified by their HR gene status, were treated with pemetrexed, cisplatin, and olaparib—alone and in combination. Lung fibroblasts were used as non-tumor controls. Apoptosis and senescence were quantified following treatment, with particular attention to the BAP1-mutated NCI-H2452 cell line. Concurrently, the authors digitally screened 91 clinical MPM samples for gene expression patterns of HR pathway members. This high-throughput transcriptomic profiling enabled the identification of BRCAness features at the patient population level, supporting the translational relevance of their in vitro findings. Key experimental metrics included the assessment of apoptosis induction, senescence rates, and changes in gene expression of prognostic markers such as Aurora Kinase A (AURKA), RAD50, and DNA damage-binding protein 2 (DDB2). These markers were evaluated for their potential to predict overall survival and treatment response.

Core Findings and Why They Matter

The study's findings underscore the heterogeneity of HR pathway defects in MPM. Approximately 10% of patient samples exhibited gene expression patterns consistent with the BRCAness phenotype (source: Borchert et al. 2019). In vitro, BAP1-mutated MPM cell lines demonstrated increased apoptosis and senescence following olaparib treatment, effects that were further potentiated by combination with cisplatin. These results support the concept that HR-defective tumors are reliant on alternative DNA repair mechanisms, such as those mediated by PARP1, and are thus vulnerable to PARP inhibition. Furthermore, the study identified AURKA, RAD50, and DDB2 gene expression levels as prognostic markers, suggesting potential utility in clinical decision-making. Importantly, the findings advocate for molecular stratification of MPM patients based on HR pathway status, which could enhance therapeutic outcomes by guiding the use of PARP inhibitors in personalized regimens.

Comparison with Existing Internal Articles

Several internal resources elaborate on the role of calcium signaling and apoptosis induction in cancer models, particularly with reference to calcium ionophores such as ionomycin calcium salt:

• Ionomycin calcium salt: Precise Calcium Ionophore for Intracellular Ca2+ Regulation discusses the use of ionomycin as a tool for modulating intracellular calcium levels and inducing apoptosis in cancer cells, with evidence for inhibition of tumor growth and modulation of the Bcl-2/Bax ratio—key regulators of the intrinsic apoptosis pathway. While Borchert et al. focus on DNA repair-mediated apoptosis and senescence, both strategies converge on programmed cell death as an anti-tumor mechanism (source: internal_article).
• Advanced Insights into Calcium Signaling and Apoptosis highlights how calcium ionophores can be used to dissect pathways of calcium-dependent apoptosis induction, supporting advanced cell signaling studies in oncology. Although the reference study by Borchert et al. does not directly address calcium signaling, both lines of research emphasize the importance of precise pathway targeting for effective cancer therapy (source: internal_article).
• Precision Calcium Ionophore for Cancer Research provides practical protocols for using ionomycin calcium salt in apoptosis and tumor inhibition studies, complementing the molecular profiling and drug sensitivity analyses described by Borchert et al. (source: internal_article).

These internal articles collectively support the use of targeted modulators—whether of calcium signaling or DNA repair pathways—as powerful tools for understanding and manipulating tumor cell death.

Limitations and Transferability

While Borchert et al. make a strong case for the use of HR pathway profiling to guide olaparib therapy, several limitations should be noted. The in vitro findings, though robust, require validation in larger, clinically annotated patient cohorts and in vivo models. The proportion of MPM tumors harboring actionable BRCAness features was approximately 10% in this study, but this may vary across populations (source: Borchert et al. 2019). Additionally, the interplay between DNA repair defects and other cellular stress pathways (e.g., calcium signaling) remains to be fully elucidated. Transferability of these results to the clinic will depend on the development of standardized, accessible assays for HR gene expression profiling, as well as carefully designed combination regimens that account for tumor heterogeneity and resistance mechanisms.

Protocol Parameters

• assay: PARP inhibitor sensitivity assay | value_with_unit: IC50 (olaparib, cell-line specific) | applicability: BAP1-mutated MPM cell lines | rationale: Determines susceptibility to PARP inhibition | source_type: paper
• assay: Gene expression profiling (HR pathway) | value_with_unit: n/a (transcriptomic profiling) | applicability: 91 clinical MPM samples | rationale: Identifies BRCAness phenotype for patient stratification | source_type: paper
• assay: Apoptosis quantification | value_with_unit: % apoptotic cells post-treatment | applicability: NCI-H2452 and other MPM lines | rationale: Measures functional response to olaparib and cisplatin | source_type: paper
• assay: Ionomycin-induced intracellular Ca2+ elevation | value_with_unit: 1–10 µM (workflow recommendation) | applicability: Cancer cell apoptosis induction studies | rationale: Standard range for modulating calcium-dependent apoptotic pathways | source_type: workflow_recommendation

Research Support Resources

For researchers seeking to explore apoptosis induction and cell signaling in cancer models—particularly in the context of DNA repair or calcium-dependent pathways—reagents such as Ionomycin calcium salt (SKU B5165) from APExBIO can facilitate precise intracellular Ca2+ modulation, supporting workflows that intersect with those described in both the Borchert et al. study and internal protocol recommendations. Utilization of validated calcium ionophores enables robust experimental interrogation of apoptosis, Bcl-2/Bax ratio dynamics, and potential synergy with targeted therapies (workflow_recommendation).